Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia

Lindsey E Roeker; Maryam Sarraf Yazdy; Joanna Rhodes; Julie Goodfriend; Mayur Narkhede; Joseph Carver; Anthony Mato

doi:10.1001/jamanetworkopen.2019.16326

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia

JAMA Netw Open. 2019 Dec 2;2(12):e1916326. doi: 10.1001/jamanetworkopen.2019.16326.

Authors

Lindsey E Roeker¹, Maryam Sarraf Yazdy², Joanna Rhodes³, Julie Goodfriend¹, Mayur Narkhede⁴, Joseph Carver⁵, Anthony Mato⁶

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
² Division of Hematology and Oncology, Department of Medicine, Georgetown University Hospital Lombardi Comprehensive Cancer Center, Washington, DC.
³ Department of Hematology and Oncology, Northwell Health Cancer Institute, New Hyde Park, New York.
⁴ Division of Hematology and Oncology, Department of Medicine, University of Alabama, Birmingham.
⁵ Cardiovascular Division, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia.
⁶ Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Abstract

This cohort study describes patterns of development, management strategies, and long-term vascular consequences of hypertension associated with ibrutinib in the non–clinical trial setting.

Publication types

Observational Study

MeSH terms

Adenine / analogs & derivatives
Adult
Antihypertensive Agents / therapeutic use*
Female
Humans
Hypertension / chemically induced*
Hypertension / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Middle Aged
Piperidines
Pyrazoles / adverse effects*
Pyrimidines / adverse effects*

Substances

Antihypertensive Agents
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States